Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement

Summary

The purpose of this research study is to evaluate the analgesic efficacy of adding a single shot parasacral (sciatic) nerve block to a continuous lumbar plexus block in patients undergoing total hip replacement.

Conditions

• Osteoarthritis of Hip
• Regional Anesthesia
• Other Acute Postoperative Pain
• Total Hip Arthroplasty
• Peripheral Nerve Block
• Lumbar Plexus Nerve Block
• Parasacaral (Sciatic) Nerve Block

Interventions

PROCEDURE

Continuous Lumbar Plexus Block

Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.

PROCEDURE

Parasacral Nerve Block

A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected.

DRUG

Ropivacine 0.2%

Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm.

DRUG

Bupivacaine 0.0625%

In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.

Sponsors & Collaborators

• Rita Merman

  lead OTHER

Principal Investigators

• Rita Merman, MD · UPMC Presbyterian Shadyside

• Jacques E. Chelly, MD, PhD, MBA · UPMC Presbyterian Shadyside

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-01-31

Primary Completion

2014-06-17

Completion

2014-06-17

Countries

• United States

Study Locations